Galina Kurteva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Galina Kurteva has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
L. Balabanski
Hospital “Malinov
3 shared publicationsN. Chilingirova
Specialized Hospital for Active Treatment in Oncology (National Center of Oncology)
3 shared publicationsP. Chilingirov
Complex Oncology Center
3 shared publicationsD. Damyanov
2 shared publicationsD. Toncheva
2 shared publications- Alberto Bernareggi
Helsinn Healthcare SA, Via Pian Scairolo 9, 6912 Pazzallo (Lugano), Switzerland
1 shared publication
Latest Publications
- 1 November 2019
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 139, 105041
Pharmacokinetic profile and safety of intravenous NEPA, a fixed combination of fosnetupitant and palonosetron, in cancer patients: Prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy
- 1 November 2019
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 139, 105041
Pharmacokinetic profile and safety of intravenous NEPA, a fixed combination of fosnetupitant and palonosetron, in cancer patients: Prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy
- 8 December 2015
- Published by Springer Nature in memo - Magazine of European Medical Oncology
- Vol. 9 (1) , 30-38
TruSight Cancer Sequencing Panel reveals pharmacogenetic variants associated with sensitivity to chemotherapy in lung cancer
- 8 December 2015
- Published by Springer Nature in memo - Magazine of European Medical Oncology
- Vol. 9 (1) , 30-38
TruSight Cancer Sequencing Panel reveals pharmacogenetic variants associated with sensitivity to chemotherapy in lung cancer
- 1 September 2015
- Published by Elsevier in European Journal of Cancer
- Vol. 51, S612-S613
3050 Detection of driver mutation heterogeneity in patients with non-small cell lung cancer (NSCLC) using next generation sequencing (NGS)
- 1 September 2015
- Published by Elsevier in European Journal of Cancer
- Vol. 51, S612-S613
3050 Detection of driver mutation heterogeneity in patients with non-small cell lung cancer (NSCLC) using next generation sequencing (NGS)
- 16 March 2015
- Published by Elsevier in Annals of Oncology
- Vol. 26, i1-i5
Identifying the Genetic Landscape of Squamous Cell Carcinoma (SCC) and Adenosquamous Carcinoma (ASC) of the Lung Using Next-Generation Sequencing (NGS)
- 16 March 2015
- Published by Elsevier in Annals of Oncology
- Vol. 26, i1-i5
Identifying the Genetic Landscape of Squamous Cell Carcinoma (SCC) and Adenosquamous Carcinoma (ASC) of the Lung Using Next-Generation Sequencing (NGS)
- Open Access
Success of Chemotherapy in Soft Matter
The success of chemotharapy in soft matter as a survival is found in the paper. Therefore, it is found the analogous tumor stretching force in soft matter; ultrasonography is performed for this tumor; restoration in soft matter with such a tumor is found; Bayes estimate of the probability of chemotherapy success is derived from the transferred chemical energy and from soft matter entropy; survival probability is juxtaposed to this probability of success.
Open AccessSuccess of Chemotherapy in Soft Matter
The success of chemotharapy in soft matter as a survival is found in the paper. Therefore, it is found the analogous tumor stretching force in soft matter; ultrasonography is performed for this tumor; restoration in soft matter with such a tumor is found; Bayes estimate of the probability of chemotherapy success is derived from the transferred chemical energy and from soft matter entropy; survival probability is juxtaposed to this probability of success.
- 18 June 2010
- Published by Springer Nature in memo - Magazine of European Medical Oncology
- Vol. 3 (2) , 49-52
Imatinib mesylate in the management of gastrointestinal stromal tumours (GIST)
- 18 June 2010
- Published by Springer Nature in memo - Magazine of European Medical Oncology
- Vol. 3 (2) , 49-52
Imatinib mesylate in the management of gastrointestinal stromal tumours (GIST)